2022-09-29-世界卫生组织-A_H9N2_-_Southern_hemisphere_2023_2页_208kb

WHO Global Influenza Surveillance and Response System (GISRS) conducts antigenic and genetic analyses for A(H9N2) candidate vaccine viruses. Several viruses have passed safety testing and are available for handling under BSL-2 enhanced containment, including strains like A/Hong Kong/1073/99 (G1 wild type), A/chicken/Hong Kong/Y280/G9 (G9 reassortant), and others from institutions such as NIBSC, CDC, and CCDC. National or regional control authorities approve vaccine formulations. Additional viruses, such as A/Anhui-Lujiang/39/2018 and A/Oman/2747/2019, are in preparation. Reference reagents, including sheep antisera and purified HA, are available from specified sources. Institutes like NIBSC, CDC, and CCDC handle orders and provide details for inquiries.